Genomic Profiling in Glioma Patients to Explore Clinically Relevant Markers
Author Information
Author(s): Varachev Viacheslav, Susova Olga, Mitrofanov Alexei, Naskhletashvili David, Krasnov George, Ikonnikova Anna, Bezhanova Svetlana, Semenova Vera, Sevyan Nadezhda, Prozorenko Evgenii, Ammour Yulia, Bekyashev Ali, Nasedkina Tatiana, Majchrzak-Celińska Aleksandra
Primary Institution: N.N. Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation
Hypothesis
The study aimed to investigate the genomic landscape in different subgroups of adult diffuse glioma and understand the clinical implications and associations with clinical characteristics.
Conclusion
The study found that lower tumor grade and IDH1/2 mutations are independent factors of better prognosis in glioma patients.
Supporting Evidence
- The study included 131 patients with diffuse glioma.
- IDH1/2 mutations were found in 78% of low-grade glioma patients.
- In high-grade glioma patients, TERTp mutation and PTEN deletion were markers of poor prognosis.
- Overall survival of more than 36 months was recorded in 25% of patients.
Takeaway
Researchers looked at the genes in glioma patients to find out which ones are important for treatment and survival.
Methodology
The study sequenced paired tumor and normal samples from 131 glioma patients using a panel of 812 cancer-related genes.
Potential Biases
The study did not account for the extent of intraoperative interventions, which could influence outcomes.
Limitations
The study had a small sample size and used different gene panels for sequencing, which may affect the results.
Participant Demographics
Among 131 patients, 69 were males and 62 were females, with a median age of 58 years.
Statistical Information
P-Value
p<0.0001
Confidence Interval
95%CI, 19.5–38
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website